Welcome to our dedicated page for Silo Pharma news (Ticker: SILO), a resource for investors and traders seeking the latest updates and insights on Silo Pharma stock.
Silo Pharma develops novel therapeutics and drug-delivery systems for stress-induced psychiatric disorders, chronic pain and central nervous system diseases, while also disclosing activity in cryptocurrency treasury and AI infrastructure initiatives. Company news frequently centers on SPC-15, an intranasal serotonin 5-HT4 receptor agonist program for PTSD and anxiety, as well as other pipeline work involving psychedelic-derived and traditional therapeutic approaches.
Recurring updates include patent allowances and applications in key jurisdictions, FDA and federal-policy context for psychedelic medicines, clinical-development planning, and new CNS discovery initiatives such as ibogaine-based approaches for traumatic brain injury. Corporate news also covers common-stock repurchase authorization, equity-financed asset purchases, the QwikAgents AI-agent platform, and cryptocurrency-related software assets.
Silo Pharma (Nasdaq: SILO) filed a provisional USPTO patent titled “Compositions and Methods for Treating Traumatic Brain Injuries and/or Disorders Associated therewith with Ibogaine.” The company will evaluate ibogaine and related compounds for TBI and associated neuropsychiatric conditions, citing reported structural brain changes and symptom reductions after single treatments. The release notes a projected $6.0 billion global TBI therapeutics market by 2032 and references recent federal actions to accelerate psychedelic drug development.
Silo Pharma (NASDAQ: SILO) welcomed coordinated U.S. federal actions on April 29, 2026 that accelerate psychedelic therapeutic research and regulatory clarity for PTSD and related disorders. Key developments include ARPA-H EVIDENT initial awardees (including Johns Hopkins), FDA issuance of three Commissioner’s National Priority Vouchers, an IND clearance to DemeRx NB, and a promised final guidance on psychedelic drug development to be published imminently.
Silo frames these moves as validating data-driven approaches to complex neurological and psychiatric conditions and says the federal actions could lay groundwork for new PTSD therapies.
Silo Pharma (Nasdaq: SILO) acquired assets of Qwikagents.ai and launched a dedicated AI subsidiary to expand into the AI agent market. The firm cites market projections of $47–$53 billion by 2030 and 43–50% annual growth. Silo also plans to submit an IND for SPC-15 to the FDA and advance its PTSD program into Phase 1 after approval.
The move creates a second business line—AI infrastructure—while retaining focus on clinical development.
Silo Pharma (NASDAQ: SILO) highlighted its lead intranasal PTSD candidate, SPC-15, and said it is positioned to benefit from renewed federal focus on psychedelic-based therapies following an April 18, 2026 executive order directing agencies to accelerate research.
SPC-15 is a 5-HT4 receptor agonist delivered intranasally via a nose-to-brain device, advanced under a 505(b)(2) regulatory pathway, backed by Columbia University-licensed IP, and preparing for IND engagement with the FDA.
Silo Pharma (Nasdaq: SILO) announced the European Patent Office issued a Rule 71(3) communication indicating intent to grant a patent (European Application No. 20786878.7) covering prophylactic use of 5-HT4 receptor agonists to prevent stress-induced fear and depressive-like behavior.
The allowance expands Silo's licensed IP from Columbia University, may protect major European markets once granted, and the company is evaluating Unitary Patent and national validations to maximize coverage.
Silo Pharma (Nasdaq: SILO) announced a board-authorized share repurchase program on February 23, 2026 to acquire up to $1,000,000 of its common stock. The program permits purchases on the open market or in privately negotiated transactions, subject to SEC rules and blackout periods.
The company reported 13,318,273 shares outstanding as of November 13, 2025. The program does not obligate the company to buy any specific number of shares and may be suspended or discontinued at the company's discretion.
Silo Pharma (Nasdaq: SILO) received a Notice of Allowance from the Japan Patent Office for a patent application covering SPC-15, its novel intranasal therapeutic targeting PTSD.
The allowed application, titled “Compositions and Methods for the Prevention of Stress-Induced Fear, Depression-Like Behavior, and Anxiety-Like Behavior,” covers composition and method claims and expands Silo’s international intellectual property estate in a key pharmaceutical jurisdiction.
Silo Pharma (Nasdaq: SILO) announced a non-binding Letter of Intent dated Dec. 30, 2025 with Allucent (US) LLC to support Phase 1 clinical development of SPC-15 nasal spray.
The LOI covers planning for two planned Phase 1 studies in healthy subjects: an open-label Single Ascending Dose (SAD) study and an open-label Multiple Ascending Dose (MAD) study. Allucent and Silo intend to negotiate a Master Services Agreement and project-specific Work Order covering clinical operations, pharmacovigilance, data management, biostatistics, clinical pharmacology modeling & simulation, and medical writing.
The LOI outlines proposed payment terms, including an upfront amount for direct service fees and pass-through costs to be reconciled against final invoices. Management described the LOI as a potential step toward generating safety and pharmacokinetic data for SPC-15.
Silo Pharma (Nasdaq: SILO) selected Allucent, a global clinical research organization, to support final preparations and its planned FDA IND submission in 2026 for a Phase 1 first-in-human trial of intranasal SPC-15 as a therapeutic for PTSD.
The company expects IND-enabling GLP toxicology/toxicokinetic data and a drug-device study for its formulation-specific intranasal spray system in early 2026, and intends to pursue the FDA’s 505(b)(2) accelerated pathway. Trial start is contingent on FDA IND approval; Silo described Allucent’s role as preparing dose-ranging protocols to assess SPC-15 pharmacokinetics and safety.
Silo Pharma (NASDAQ: SILO) announced on October 29, 2025 that it selected the Alphaledger/Simplify Target 12% Distribution Fund (Alphaledger T12 Fund) as a core element of its tokenized real-world asset (RWA) strategy on the Solana blockchain.
The fund is described as a digital-native vehicle focused on tokenized RWAs, offering high monthly income via a mix of high-yield, low-duration fixed income, hedged credit, and options strategies while leveraging Solana for high-speed, low-cost execution.
Silo framed the allocation as a treasury diversification move intended to generate yield and reduce portfolio volatility while integrating decentralized infrastructure with its crypto and fintech initiatives.